• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血清单不饱和三酰甘油预测非酒精性脂肪性肝病合并慢性乙型肝炎患者的脂肪性肝炎。

Serum Monounsaturated Triacylglycerol Predicts Steatohepatitis in Patients with Non-alcoholic Fatty Liver Disease and Chronic Hepatitis B.

机构信息

Center for Fatty Liver, Department of Gastroenterology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.

CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China.

出版信息

Sci Rep. 2017 Sep 5;7(1):10517. doi: 10.1038/s41598-017-11278-x.

DOI:10.1038/s41598-017-11278-x
PMID:28874844
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5585331/
Abstract

Chronic liver disease is associated with lipid metabolic disruption. We carried out a study to determine serum lipidomic features of patients with non-alcoholic fatty liver disease (NAFLD) and active chronic hepatitis B (CHB) and explored the biomarkers for non-alcoholic steatohepatitis (NASH). Serum lipidomic profiles of healthy controls (n = 23) and of biopsy-proven NAFLD (n = 42), CHB with NAFLD (n = 22) and without NAFLD (n = 17) were analyzed by ultra-performance liquid chromatography-tandem mass spectrometry. There were distinct serum lipidome between groups of NAFLD and CHB without NAFLD. Most of the neutral lipids and ceramide were elevated in the NAFLD group but were decreased in the CHB without NAFLD group. Plasmalogens were decreased in both groups. Triacylglycerols (TAGs) with lower carbon numbers and double bonds were increased in subjects with NASH. Serum monounsaturated TAG was a significant predictor of NASH (OR = 3.215; 95%CI 1.663-6.331) and positively correlated with histological activity (r = 0.501; P < 0.001). It showed good predictability for NASH in the NAFLD group [area under the receiver operating characteristic curves (AUROC) = 0.831] and was validated in the CHB group (AUROC = 0.833); this characteristic was superior to that of cytokeratin-18 and alanine transaminase. The increase in monounsaturated TAG might be a specific marker for NASH in both NAFLD and CHB patients.

摘要

慢性肝脏疾病与脂质代谢紊乱有关。我们进行了一项研究,以确定非酒精性脂肪性肝病 (NAFLD) 和活动性慢性乙型肝炎 (CHB) 患者的血清脂质组学特征,并探讨了非酒精性脂肪性肝炎 (NASH) 的生物标志物。通过超高效液相色谱-串联质谱法分析了健康对照组(n=23)和经活检证实的 NAFLD(n=42)、伴有和不伴有 NAFLD 的 CHB(n=22)和 17)的血清脂质组学图谱。NAFLD 和不伴有 NAFLD 的 CHB 组之间的血清脂质组有明显差异。NAFLD 组的大多数中性脂质和神经酰胺升高,但不伴有 NAFLD 的 CHB 组则降低。两组的鞘脂都减少了。NASH 患者的TAG 中具有较低碳原子数和双键的三酰基甘油增加。血清单不饱和 TAG 是 NASH 的一个显著预测因子(OR=3.215;95%CI 1.663-6.331),并与组织学活动呈正相关(r=0.501;P<0.001)。它在 NAFLD 组对 NASH 具有良好的预测能力[受试者工作特征曲线下面积(AUROC)=0.831],并在 CHB 组得到验证(AUROC=0.833);这一特征优于细胞角蛋白 18 和丙氨酸氨基转移酶。单不饱和 TAG 的增加可能是 NAFLD 和 CHB 患者 NASH 的特异性标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b662/5585331/07d99130534d/41598_2017_11278_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b662/5585331/0be2cacf3c50/41598_2017_11278_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b662/5585331/33e139108ee8/41598_2017_11278_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b662/5585331/e665b0a026cb/41598_2017_11278_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b662/5585331/23c993d417de/41598_2017_11278_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b662/5585331/07d99130534d/41598_2017_11278_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b662/5585331/0be2cacf3c50/41598_2017_11278_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b662/5585331/33e139108ee8/41598_2017_11278_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b662/5585331/e665b0a026cb/41598_2017_11278_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b662/5585331/23c993d417de/41598_2017_11278_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b662/5585331/07d99130534d/41598_2017_11278_Fig5_HTML.jpg

相似文献

1
Serum Monounsaturated Triacylglycerol Predicts Steatohepatitis in Patients with Non-alcoholic Fatty Liver Disease and Chronic Hepatitis B.血清单不饱和三酰甘油预测非酒精性脂肪性肝病合并慢性乙型肝炎患者的脂肪性肝炎。
Sci Rep. 2017 Sep 5;7(1):10517. doi: 10.1038/s41598-017-11278-x.
2
Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.严重肥胖症中的肝脂质组学重塑表现为脂肪变性,且不会随着非酒精性脂肪性肝炎而进展。
J Hepatol. 2021 Sep;75(3):524-535. doi: 10.1016/j.jhep.2021.04.013. Epub 2021 Apr 20.
3
Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).丙氨酸氨基转移酶水平对非酒精性脂肪性肝病患者非酒精性脂肪性肝炎(NASH)和肝纤维化的预测价值。
Liver Int. 2013 Oct;33(9):1398-405. doi: 10.1111/liv.12226. Epub 2013 Jun 13.
4
Interleukin-21 Is Associated with Early Antiviral Response in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B and Nonalcoholic Fatty Liver Disease.白细胞介素-21与乙肝e抗原阳性慢性乙型肝炎和非酒精性脂肪性肝病患者的早期抗病毒反应相关。
J Interferon Cytokine Res. 2016 Jun;36(6):367-73. doi: 10.1089/jir.2015.0129. Epub 2016 Feb 3.
5
Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population.疾病特异性miR-34a作为中国人群非酒精性脂肪性肝炎的诊断标志物。
World J Gastroenterol. 2016 Nov 28;22(44):9844-9852. doi: 10.3748/wjg.v22.i44.9844.
6
Circulating lipidomic alterations in obese and non-obese subjects with non-alcoholic fatty liver disease.非酒精性脂肪性肝病肥胖和非肥胖患者循环脂质组学改变。
Aliment Pharmacol Ther. 2020 Nov;52(10):1603-1614. doi: 10.1111/apt.16066. Epub 2020 Sep 6.
7
The gamma-glutamyl transpeptidase to platelet ratio for non-invasive assessment of liver fibrosis in patients with chronic hepatitis B and non-alcoholic fatty liver disease.γ-谷氨酰转肽酶与血小板比值用于慢性乙型肝炎和非酒精性脂肪性肝病患者肝纤维化的无创评估
Oncotarget. 2017 Apr 25;8(17):28641-28649. doi: 10.18632/oncotarget.16162.
8
Thyroid function is associated with non-alcoholic fatty liver disease in chronic hepatitis B-infected subjects.甲状腺功能与慢性乙型肝炎感染患者的非酒精性脂肪性肝病相关。
J Gastroenterol Hepatol. 2015 Dec;30(12):1753-8. doi: 10.1111/jgh.12998.
9
Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients.脂肪肝进展算法和脂肪变性、活动度及纤维化评分在评估非酒精性脂肪肝对未经治疗的慢性乙型肝炎患者影响中的应用。
Front Cell Infect Microbiol. 2022 Jan 17;11:733348. doi: 10.3389/fcimb.2021.733348. eCollection 2021.
10
Circulating Phospholipid Patterns in NAFLD Patients Associated with a Combination of Metabolic Risk Factors.非酒精性脂肪性肝病患者与代谢危险因素组合相关的循环磷脂谱。
Nutrients. 2018 May 21;10(5):649. doi: 10.3390/nu10050649.

引用本文的文献

1
Role of AMPK2 in regulating the IRE1JNK pathway in metabolic dysfunctionassociated fatty liver disease.AMPK2在代谢功能障碍相关脂肪性肝病中调节IRE1-JNK信号通路的作用
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024 Dec 28;49(12):1891-1901. doi: 10.11817/j.issn.1672-7347.2024.240474.
2
Plasma Lipids Profile in the Prediction of Non-Alcoholic Steatohepatitis in Adults: A Case-Control Study.血浆脂质谱在成人非酒精性脂肪性肝炎预测中的作用:一项病例对照研究。
Int J Mol Sci. 2023 Aug 12;24(16):12717. doi: 10.3390/ijms241612717.
3
Advance of Serum Biomarkers and Combined Diagnostic Panels in Nonalcoholic Fatty Liver Disease.

本文引用的文献

1
A noninvasive diagnostic model to assess nonalcoholic hepatic steatosis in patients with chronic hepatitis B.一种用于评估慢性乙型肝炎患者非酒精性肝脂肪变性的非侵入性诊断模型。
Therap Adv Gastroenterol. 2017 Feb;10(2):207-217. doi: 10.1177/1756283X16681707. Epub 2016 Dec 15.
2
Protective role of endogenous plasmalogens against hepatic steatosis and steatohepatitis in mice.内源性缩醛磷脂对小鼠肝脏脂肪变性和脂肪性肝炎的保护作用。
Hepatology. 2017 Aug;66(2):416-431. doi: 10.1002/hep.29039. Epub 2017 Jun 29.
3
Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study.
血清生物标志物和联合诊断标志物在非酒精性脂肪性肝病中的研究进展。
Dis Markers. 2022 Jun 29;2022:1254014. doi: 10.1155/2022/1254014. eCollection 2022.
4
A Novel Noninvasive Diagnostic Model of HBV-Related Inflammation in Chronic Hepatitis B Virus Infection Patients With Concurrent Nonalcoholic Fatty Liver Disease.慢性乙型肝炎病毒感染合并非酒精性脂肪性肝病患者中一种新型的HBV相关炎症无创诊断模型
Front Med (Lausanne). 2022 Mar 23;9:862879. doi: 10.3389/fmed.2022.862879. eCollection 2022.
5
Defining NASH from a Multi-Omics Systems Biology Perspective.从多组学系统生物学角度定义非酒精性脂肪性肝炎
J Clin Med. 2021 Oct 12;10(20):4673. doi: 10.3390/jcm10204673.
6
rs2070667 Associates with Serum Triglyceride Profile and Hepatic Inflammation in Nonalcoholic Fatty Liver Disease.rs2070667 与非酒精性脂肪性肝病患者的血清甘油三酯谱和肝炎症相关。
Biomed Res Int. 2020 Nov 26;2020:8869674. doi: 10.1155/2020/8869674. eCollection 2020.
7
A New Endemic of Concomitant Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B.非酒精性脂肪性肝病与慢性乙型肝炎并存的一种新的地方病
Microorganisms. 2020 Oct 4;8(10):1526. doi: 10.3390/microorganisms8101526.
8
Liquid Biopsy for the Diagnosis of Viral Hepatitis, Fatty Liver Steatosis, and Alcoholic Liver Diseases.液体活检在病毒性肝炎、脂肪性肝病和酒精性肝病诊断中的应用。
Int J Mol Sci. 2020 May 25;21(10):3732. doi: 10.3390/ijms21103732.
9
Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy.用于癌前肝病诊断和治疗的代谢组学和脂质组学生物标志物
Metabolites. 2020 Jan 28;10(2):50. doi: 10.3390/metabo10020050.
10
Multi-technique comparison of atherogenic and MCD NASH models highlights changes in sphingolipid metabolism.多技术比较动脉粥样硬化和 MCD NASH 模型,突出了鞘脂代谢的变化。
Sci Rep. 2019 Nov 14;9(1):16810. doi: 10.1038/s41598-019-53346-4.
乙型肝炎病毒感染与非酒精性脂肪性肝病风险降低的相关性:一项队列研究。
Hepatology. 2017 Mar;65(3):828-835. doi: 10.1002/hep.28917. Epub 2016 Dec 30.
4
The prevalence of steatohepatitis in chronic hepatitis B patients and its impact on disease severity and treatment response.慢性乙型肝炎患者中脂肪性肝炎的患病率及其对疾病严重程度和治疗反应的影响。
Liver Int. 2017 Apr;37(4):542-551. doi: 10.1111/liv.13271. Epub 2016 Oct 31.
5
Discovering a critical transition state from nonalcoholic hepatosteatosis to nonalcoholic steatohepatitis by lipidomics and dynamical network biomarkers.通过脂质组学和动态网络生物标志物发现从非酒精性肝脂肪变性到非酒精性脂肪性肝炎的关键过渡状态。
J Mol Cell Biol. 2016 Jun;8(3):195-206. doi: 10.1093/jmcb/mjw016. Epub 2016 Mar 18.
6
Relationship between chronic hepatitis B and metabolic syndrome: A structural equation modeling approach.慢性乙型肝炎与代谢综合征之间的关系:一种结构方程建模方法。
Obesity (Silver Spring). 2016 Feb;24(2):483-9. doi: 10.1002/oby.21333. Epub 2015 Dec 31.
7
Recent progress in the discovery and development of stearoyl CoA desaturase inhibitors.硬脂酰辅酶A去饱和酶抑制剂发现与开发的最新进展
Chem Phys Lipids. 2016 May;197:3-12. doi: 10.1016/j.chemphyslip.2015.08.018. Epub 2015 Sep 3.
8
Characterization of hepatic lipid profiles in a mouse model with nonalcoholic steatohepatitis and subsequent fibrosis.非酒精性脂肪性肝炎及随后纤维化小鼠模型中肝脏脂质谱的特征分析
Sci Rep. 2015 Aug 20;5:12466. doi: 10.1038/srep12466.
9
Adipocytokines and liver fibrosis stages in patients with chronic hepatitis B virus infection.慢性乙型肝炎病毒感染患者的脂肪细胞因子与肝纤维化分期
Hepatol Int. 2015 Apr;9(2):231-42. doi: 10.1007/s12072-015-9616-2. Epub 2015 Mar 12.
10
Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease.皮肤-包膜距离对慢性肝病患者受控衰减参数性能的影响。
Liver Int. 2015 Nov;35(11):2392-400. doi: 10.1111/liv.12809. Epub 2015 Mar 6.